Patents by Inventor Timothy F. Gallagher

Timothy F. Gallagher has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5783664
    Abstract: This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.
    Type: Grant
    Filed: May 31, 1994
    Date of Patent: July 21, 1998
    Assignee: SmithKline Beecham Corporation
    Inventors: John C. Lee, Jerry L. Adams, Timothy F. Gallagher, David W. Green, John Richard Heys, Peter C. McDonnell, Dean E. McNulty, James E. Strickler, Peter R. Young
  • Patent number: 5777097
    Abstract: This invention relates to drug binding proteins, to genes encoding same and to assays and methods for screening pharmaceuticals. More specifically, this invention relates to a Cytokine Suppressive Anti-Inflammatory Drug (CSAID) binding protein, to a gene encoding same and to assays and screens useful in the evaluation and characterization of drugs of this pharmacologic class.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: July 7, 1998
    Assignee: SmithKline Beecham Corporation
    Inventors: John C. Lee, Jerry L. Adams, Timothy F. Gallagher, David W. Green, John Richard Heys, Peter C. McDonnell, Dean E. McNulty, Peter R. Young, James E. Strickler
  • Patent number: 5593992
    Abstract: Novel 1,4,5-substituted imidazole compounds and compositions for use in therapy as cytokine inhibitors.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 14, 1997
    Assignee: SmithKline Beecham Corporation
    Inventors: Jerry L. Adams, Peter W. Sheldrake, Timothy F. Gallagher, Ravishanker Garigipati
  • Patent number: 5068248
    Abstract: Method for increasing resistance to gastro-intestinal irritation, and for the treatment of pain, fever, inflammation, arthritic conditions, asthma, allergic disorders, skin diseases, cardiovascular disorders, psoriasis, inflammatory bowel disease, glaucoma or other prostaglandin and/or leukotriene mediated diseases comprising the administration to a subject in need of such treatment, a non-toxic therapeutically effective amount of compound of formula I: ##STR1##
    Type: Grant
    Filed: June 22, 1989
    Date of Patent: November 26, 1991
    Assignee: Merck & Co., Inc.
    Inventors: Allan N. Tischler, Philippe L. Durette, Bruce E. Witzel, Kathleen M. Rupprecht, Timothy F. Gallagher, Marvin M. Goldenberg, Debra L. Allison
  • Patent number: 5023250
    Abstract: New 14.alpha.-carboxyalkyl sterols are regulators of HMG-CoA reductase and inhibitors of mammalian 14.alpha.-methyl demethylase and are useful in lowering serum cholesterol levels and treating fungal infections.
    Type: Grant
    Filed: August 24, 1989
    Date of Patent: June 11, 1991
    Assignee: SmithKline Beecham Corporation
    Inventors: Jerry L. Adams, Timothy F. Gallagher, Ruth J. Mayer, Brian W. Metcalf
  • Patent number: 4894392
    Abstract: Disclosed are specific aminoalkyl naphthalenediol derivatives that enhance host resistance to infectious organisms. Such agents are administered prophylactically to individuals whose resistance to infection is comprised by chemotherapy, surgery, burns or other forms of severe stress.
    Type: Grant
    Filed: May 12, 1988
    Date of Patent: January 16, 1990
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Timothy F. Gallagher
  • Patent number: 4760086
    Abstract: N-Alkenyl-3-hydroxybenzo[b]thiophene-2-carboxamide derivatives have been prepared by:(1) treating a substituted 2-halobenzoate with thioacetamide followed by N-alkenylation with appropriate agents, such as aldehydes, ketones, enol ethers, epoxides, acetals or ketals;(2) treating a substituted thiosalicylate with an appropriately substituted haloacetamide, followed by dehydration; and(3) further synthetic modification of compounds prepared above.These compounds have been found to be effective inhibitors of both cyclooxygenase and lipoxygenase and thereby useful in the treatment of pain, fever, inflammation, arthritic conditions, asthma, allergic disorders, skin diseases, cardiovascular disorders, psoriasis, inflammatory bowel disease, glaucoma or other prostaglandins and/or leukotriene mediated diseases.
    Type: Grant
    Filed: February 27, 1985
    Date of Patent: July 26, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Allan N. Tischler, Bruce E. Witzel, Philippe L. Durette, Kathleen M. Rupprecht, Timothy F. Gallagher, Debra L. Allison, Marvin M. Goldenberg
  • Patent number: 4760161
    Abstract: Compounds of the Formula I: ##STR1## and pharmaceutically acceptable salts thereof are inhibitors of leukotriene biosynthesis. These compounds inhibit lipoxygenase, thus preventing the metabolism of arachidonic acid to the leukotrienes. These compounds are thus useful in the treatment of asthma, allergic disorders, inflammation, skin diseases and certain cardiovascular disorders.
    Type: Grant
    Filed: April 25, 1983
    Date of Patent: July 26, 1988
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Timothy F. Gallagher
  • Patent number: 4663344
    Abstract: 3-Hydroxybenzo[b]thiophene derivatives, such as 2-aralkyl, 2-alkyl and 2-alkenyl-3-hydroxybenzo[b]-thiophenes, were prepared by, among other methods, ring closure of 2-(2-carboxy-phenylthio)-.alpha.-substituted acetic acids. These compounds are found to be useful in the treatment of pain, fever, inflammation, arthritic conditions, asthma, allergic disorders, skin diseases, cardiovascular disorders, psoriasis, inflammatory diseases and other prostaglandin and/or leukotriene mediated diseases.
    Type: Grant
    Filed: March 11, 1985
    Date of Patent: May 5, 1987
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Bruce E. Witzel, Kathleen M. Rupprecht, Allan N. Tischler, Timothy F. Gallagher
  • Patent number: 4526999
    Abstract: Compounds of the Formula I: ##STR1## and pharmaceutically acceptable salts thereof are inhibitors of leukotriene biosynthesis. These compounds inhibit lipoxygenase, thus preventing the metabolism of arachidonic acid to the leukotrienes. These compounds are thus useful in the treatment of asthma, allergic disorders, inflammation, skin diseases and certain cardiovascular disorders.
    Type: Grant
    Filed: April 25, 1983
    Date of Patent: July 2, 1985
    Assignee: Merck & Co., Inc.
    Inventors: Philippe L. Durette, Timothy F. Gallagher
  • Patent number: 4515722
    Abstract: Phosphatidyl inositol analogs are found to be effective phospholipase C inhibitors and thereby potent anti-inflammatory and analgesic agents. These phosphatidyl inositol analogs are prepared by condensation of a protected inositol with a substituted phosphonic or phosphorous acid followed by removal of protecting groups.
    Type: Grant
    Filed: March 30, 1982
    Date of Patent: May 7, 1985
    Assignee: Merck & Co., Inc.
    Inventors: Shu S. Yang, Thomas R. Beattie, Philippe L. Durette, Timothy F. Gallagher, Tsung-Ying Shen